Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Northpond Ventures, LLC (CIK 1911245) reported $43.7M across 3 reported positions in its SEC 13F filing for 2024-09-30. Largest positions: KYTX ($15.9M, 36.46%), VIGL ($14.3M, 32.82%), CADL ($13.4M, 30.72%), TBIO ($0, 0.00%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | KYTX | KYVERNA THERAPEUTICS INC | $15.9M | 36.46% | 3.3M | Hold |
| 2 | VIGL | VIGIL NEUROSCIENCE INC | $14.3M | 32.82% | 4.2M | Hold |
| 3 | CADL | CANDEL THERAPEUTICS INC | $13.4M | 30.72% | 1.9M | Hold |
| 4 | TBIO | TELESIS BIO INC | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2024-09-30